Editorial: Promises to keep
By Los Angeles Times,
Los Angeles Times
| 01. 17. 2006
AT THE HEART OF CALIFORNIA'S multibillion-dollar experiment in public stem cell research are two promises. One is that such research will save lives. The other is that the scientists conducting it, and the agency funding it, will be accountable. The first is as magnificent as it is exaggerated; the second is more practical but as yet unfulfilled.
That's the bad news. The good news is that there's still time for the state agency set up by Proposition 71, which created a $3-billion bond to fund such research, to make good on its promise. All it will take is compromise, common sense _ and maybe a little litigation. The last of these, at least, is starting to have an effect.
Research in the public interest
Any undertaking this big was bound to have early stumbles, but the first year under the stem cell initiative was especially disappointing. To start, the initiative itself has multiple flaws, most of them related to accountability.
The California Institute of Regenerative Medicine was created by Proposition 71, which also freed it from most public oversight and...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...